Nplate (romiplostim)

Supportive care included epoetin alfa, romiplostim, iron, and vitamin supplementation. CONCLUSIONS This is the first known reported case that demonstrates the feasibility and effectiveness of a chemotherapy-free induction strategy using inotuzumab and blinatumomab for frontline treatment of Ph-negative B-ALL in Jehovah's Witness patients. It shows that MRD negativity can be safely achieved without cytotoxic chemotherapy or transfusion support and supports the use of the ALLIANCE A041703 trial regimen as a treatment model for this unique and underserved patient group.

P=N/A, N=88, Not yet recruiting, The First Affiliated Hospital of Guilin Medical University; The First Affiliated Hospital of Guilin Medical University

P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University

P=N/A, N=120, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University

P4, N=35, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

P4, N=30, Not yet recruiting, Jiangxi Cancer Hospital; Jiangxi Cancer Hospital

P3, N=60, Not yet recruiting, The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University

P2, N=60, Not yet recruiting, TThe Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen); The Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)

P3, N=145, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

P3, N=210, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

Consistent with these changes in priming, platelets aged in vitro exhibit increasing expression of multiple pro-apoptotic proteins including BIM, BAK and PUMA along with increasing cleaved caspase 3. Leveraging the lower BCL-XL dependence of young platelets, stimulation of de novo platelet production with the thrombopoietin receptor agonist romiplostim prevents BH3 mimetic-induced thrombocytopenia in vivo and may prevent severe platelet loss in patients treated with BCL-XL inhibitors.

P1, N=130, Recruiting, First Affiliated Hospital of Zhejiang University